Targacept to Report First Quarter 2013 Financial Results on May 7, 2013 Business Wire WINSTON-SALEM, N.C. -- April 30, 2013 Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that it will report financial results for the first quarter of 2013 on the morning of Tuesday, May 7, 2013, before the U.S. financial markets open. Management will discuss the first quarter financial results, provide a business and program update and discuss expectations for the future via conference call at 8:30 a.m. Eastern Time on Tuesday, May 7, 2013. The conference call may be accessed by dialing 866.515.2913 for domestic participants and 617.399.5127 for international callers (reference passcode 92922085). A replay of the conference call may be accessed beginning approximately two hours following the call on May 7, 2013 through May 21, 2013 by dialing 888.286.8010 for domestic callers and 617.801.6888 for international callers (reference passcode 98152896). A live audio webcast of the conference call will be accessible from the Investor Relations page of Targacept’s website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available for replay on the Investor Calendar section of the Investor Relations page of Targacept’s website for at least two weeks following the call. About Targacept Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, unique proteins that regulate vital biological functions that are impaired in various disease states. Targacept’s clinical pipeline includes multiple Phase 2 product candidates, all representing first-in-class opportunities. Targacept leverages its scientific leadership and diverse pipeline to attract significant collaborations with global pharmaceutical companies. For more information, please visit www.targacept.com. TARGACEPT Building Health, Restoring Independence^® Contact: Targacept, Inc. Alan Musso, 336-480-2186 SVP, Finance and Administration and CFO email@example.com or Linnden Communications Michelle Linn, 508-362-3087 firstname.lastname@example.org
Targacept to Report First Quarter 2013 Financial Results on May 7, 2013
Press spacebar to pause and continue. Press esc to stop.